Select Page

The latest report on “Autoimmune Disease Drug Market (Indication – Diabetes Mellitus Type 1, Rheumatic Diseases, Multiple Sclerosis, Rare Diseases, and Other Indication; Drug Class – NSAIDs, Anti-inflammatory, Interferons, Antihyperglycemic, Immunosuppressants, and Other Drug Class; Distribution Channel – Hospital Pharmacies, Online Stores, and Retail Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025.” The global autoimmune disease drug market is projected to grow at a CAGR of 4.3% over the forecast period of 2019-2025.

For More Details Get FREE Sample Pages of this Research Report@

Autoimmune diseases are diseases caused due to dysfunction of the immune system. The immune system is the body’s defense against infections and diseases. However, sometimes the natural system of the body fails to recognize between own cells and foreign cells, leading to produce autoantibodies that kill normal cells and healthy tissues and can affect any body part. By far more than 80 autoimmune diseases are been identified which includes rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, etc. Out of these autoimmune diseases, some are life-threatening while some of them need treatment for a lifetime and some may also lead to disability. In female children and women, autoimmune disease is one of the leading causes of death.

Increasing Population of Autoimmune Disease is One of the Key Factors Driving the Autoimmune Disease Drug Market

An increasing population of autoimmune disease is one of the key factors driving the autoimmune disease drug market. As per the statistics of the National Institute of Health, approximately 23.5 million Americans have autoimmune diseases, among this 75 % are women. Moreover, initiatives taken by the government and private sector for spreading awareness regarding autoimmune disease is likely to boost the drug market.

However, late or troublesome diagnosis owing to a lack of understanding of autoimmune diseases, their causes and their symptoms may hamper the growth of the market. Additionally, the long-term side effects of the drugs may also hold back the growth of the market. Furthermore, due to a substantial rise in biopharmaceutical research companies to generate innovative approaches and drugs for disease treatment as well as raising funds for the advancement of technologies will have greater opportunities for the autoimmune disease drug market during the forecast period.

North America Dominates the Market

Geographically, the market can be segmented into North America, Europe, Asia Pacific, and RoW. North America dominates the market due to its huge population affected by autoimmune disease and increasing research activities to speed up the development of new treatment options. Europe’s market is expected to grow due to its escalation in awareness among people about autoimmune diseases and the involvement of government and private sectors to upgrade methods of diagnosis as well as prevention and management of the disease. On the other hand, the market in the Asia Pacific region is expected to grow during the forecast period owing to the considerable rise in healthcare expenditures.

Segment Covered

The report on the global autoimmune disease drug market covers segments such as indication, drug class, and distribution channel. On the basis of indication, the sub-markets include diabetes mellitus type 1, rheumatic diseases, multiple sclerosis, rare diseases, and other indication. On the basis of drug class, the sub-markets include NSAIDs, anti-inflammatory, interferons, antihyperglycemic, immunosuppressants, and other drug classes. On the basis of distribution channels, the sub-markets include hospital pharmacies, online stores, and retail pharmacies.

Browse Detailed TOC and Description of this Exclusive Report@

Companies Profiled:

The report provides profiles of the companies in the market such as F. Hoffmann-La Roche AG, Abbott Laboratories, Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson, AstraZeneca plc, Pfizer Inc., Novartis AG, and other companies.

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of the autoimmune disease drug.

=> Complete coverage of all the product type and application segments to analyze the trends, developments, and forecast of market size up to 2025.

=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.  

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.